) --Welcome to December's Biotech Stock Mailbag Live Chat. The floor is yours.
I'm here for the next 90 minutes to answer your biotech investing questions and hopefully spark some interactive debate on the hot biotech topics of the day. This chat only works if you participate, so please keep the questions and comments flowing.
Is there any hope for
future after the Libigel blow up? What about
( AIS) -- is it also mortally wounded?
announced a CEO swap this morning Surprised? Does this signal more changes in store for the company as it transitions from a focus on hepatitis C to cystic fibrosis?
We can talk about
( YMI) and what lies ahead after this week's presentation of strong data on the myelofibrosis drug CYT387. Can YM Bio's market cap catch up to that of rival
Were you confused by this week's
FDA panel? Me too, but let's hash out the future for Adasuve.
The year is almost over, so it's time to look ahead to key biotech events in 2012, including results from late-stage cancer immunotherapy trials involving
. And let's not forget that obesity drug stocks
should be volatile again in 2012.
Let's talk about these stocks today, or any other biotech investing subjects that pique your interest. Please join me live.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
and become a fan on